Lamb et al. recently reviewed the signi¢cance of raised cardiac troponin T (cTnT) concentrations in patients with kidney disease. 1 Their clearly written paper addressed a multitude of possible factors that might in£uence these cTnT measurements in uraemic patients. We recently published an article 2 that answers some speci¢c questions raised by Lamb et al. By identifying several fragments of cTnT that are small enough to accumulate in the serum of dialysis patients, and by showing the absence of intact cTnT, we can explain the elevated cTnT levels in patients without detectable acute coronary syndromes.
The main conclusion of our article was that, in most dialysis patients, two simultaneous processes occur at the same time. In previous articles, authors used cTnT concentrations for group classi¢cation in the assessment of mortality, thereby concentrating the group of patients with additional cardiovascular problems. From this, it is obvious that more cardiac damage leads to a worse outcome. In contrast, we used treatment duration instead of cTnT concentration for group classi¢cation. Despite constant CK-MB mass values indicating an even distribution of patients with additional (minor) ischaemic events, cTnT concentrations still increase with increasing duration of dialysis therapy, revealing an underlying phenomenon.
As well as this increase in cTnT concentrations due to the accumulation of cTnT fragments, a further increase can of course be caused by additional release of cTnT in cases of (minor) myocardial ischaemia. This additional release then accounts for the useful predictive value of cTnT with respect to mortality in dialysis patients. We thus clearly demonstrated that part of the increase in cTnT concentration is caused by impaired renal clearance of the fragments without a¡ecting the predictive value of cTnT.
In our opinion, cTnT can only be used in dialysis patients suspected of acute myocardial infarction when a second sample is drawn after 3-6 h. In cases of myocardial injury, the cTnT concentration in this second sample should be signi¢cantly elevated compared to the ¢rst. Another possibility, although less speci¢c for myocardial tissue, is the use of CK-MB mass in these cases.
To gain a better understanding of the mechanisms of cTnT fragmentation and accumulation, we are currently investigating the time-dependent changes in release pattern of cTnT fragments in patients with acute myocardial infarction with and without decreased renal function. Perhaps the measurement of speci¢c cTnT fragments can di¡erentiate between accumulated cTnT and recently released cTnT. 
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Authors' reply
Thank you for giving us the opportunity to comment on the letter from Diris and van Dieijen-Visser.We were extremely interested in their study data, 1 which were published simultaneously with our review. 2 The accumulation of lower (8-25 kDa) molecular mass fragments of cardiac troponin T (cTnT) in the serum of haemodialysis patients may be of relevance to the origin of raised cTnT concentrations in uraemic patients. However, as the authors point out, 1 they have not demonstrated that the fragments will cross-react in the Roche cTnT assay. Further, all of their haemodialysis patients demonstrated fragments, whereas elevation of serum cTnT concentration is not universal amongst haemodialysis patients. We will await their further studies with interest. 
